ClinicalTrials.gg
RecruitingNCT07362862ICUAWUpdated Jul 10, 2026

MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients

An interventional study of Electrical Muscle Stimulation System in Sepsis, Critical Illness and ICU-acquired Muscle Weakness, sponsored by Health Discovery Labs. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Health Discovery Labs · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.

Planned enrollment
189th of 310
50 · median 84
Started
2026
with 28 others
No phase
140 of 517
22 open now
Primary completion
2027-08
later than 60 of 98 live
Registered
497th of 517
by date

Among the 517 studies in Sepsis with a site in United States, this one is the 189th largest by planned enrollment of the 310 interventional ones that give a count, is one of 29 that started in 2026, is one of 140 with no phase, reaches primary completion later than 60 of the 98 other live ones, and was the 497th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 517 studies in Sepsis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a new medical device that sends electrical signals to the thigh muscles is safe and easy to use for people in the ICU (Intensive Care Unit) who are at risk of losing muscle strength. It will also explore whether this treatment can help slow down muscle weakening.

The main questions this study aims to answer are:

  • Do participants develop medical problems when receiving electrical muscle stimulation in the ICU?
  • Is electrical muscle stimulation a practical way to help reduce muscle weakness in critically ill patients?

Researchers will compare the control group (standard of care) to the intervention group (standard of care plus 60-minute sessions of electrical muscle stimulation daily during the ICU stay) to see if the device is safe and easy to use.

Participants will:

  • Receive either standard of care or standard of care plus electrical muscle stimulation of the thigh muscles
  • Have their muscle strength checked during the study
  • Complete a survey three months after ICU discharge to check on their recovery
03

Conditions studied

  • Sepsis
  • Critical Illness
  • ICU-acquired Muscle Weakness
  • ICU-acquired Weakness
  • ICUAW
  • Sarcopenia
  • Secondary Sarcopenia

Keywords

  • Electrical muscle stimulation
  • Electrical Impedance Myography
  • Bioimpedance
  • Rehabilitation
  • Sepsis
  • Critical illness
  • ICU-acquired weakness
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to ER or ICU within the previous 48 hours
  • APACHE II score ≥ 13
  • Meets the criteria for sepsis or severe sepsis

Exclusion criteria

Exclusion Criteria:

  • Anticipated transfer to an ICU not participating in this study
  • Myopathies (e.g. congenital)
  • Acquired myopathies with CK levels 5-times above the
  • Unable to transfer from bed to chair at baseline
  • Moribund
  • Comfort care
  • New onset deep vein thrombosis within the previous 6-months
  • in lower limb
  • Technical obstacles - fracture, burns, amputation
  • Open wound or skin abrasion at the garment application site
  • Pregnancy
  • Pacemaker and implantable cardioverter-defibrillator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Intervention Group

    Participants will receive a daily 60-minute session of electrical muscle stimulation applied to the quadriceps for up to 7 days during ICU stay or until ICU discharge, alongside standard of care.

    Device: Electrical Muscle Stimulation System

  • No intervention
    Control Group

    Participants will receive standard of care only

Interventions

  • DeviceElectrical Muscle Stimulation System

    Participants will receive electrical muscle stimulation at the level of the quadriceps using the MyokinE100 device, a closed-loop electrical muscle stimulation system. The closed-loop system monitors muscle response to electrical stimulation in real time using a biofeedback sensor and automatically adjusts stimulation intensity to achieve safe and effective muscle contractions.

06

What researchers measure

Primary outcomes

  1. Change in lower limb muscle strength assessed by MRC sum score from ICU admission to ICU discharge.

    Lower limb muscle strength will be assessed using the Medical Research Council (MRC) sum score. The MRC sum score grades voluntary muscle contraction for each muscle group from 0 (no contraction) to 5 (normal strength). Six muscle groups in lower limbs will be tested for a total best possible score of 30. A 1-point increase in MRC score per muscle group in the lower limbs is considered clinically significant.

    Time frame: Day 1 (day of enrollment) and daily in the ICU up to Day 14 or upon ICU discharge whichever comes first.

  2. Number of participants with unanticipated adverse device effects (UADE) related to MyokinE100 use from enrollment to hospital discharge.

    A single Unanticipated Adverse Device Effect (UADE) in any participant during the study is considered significant.

    Time frame: From Day 1 (enrollment) through the end of the subject's study participation at 3-months.

Secondary outcomes

  1. Change in total muscle strength assessed by MRC sum score from ICU admission to ICU discharge.

    Upper and lower limb muscle strength will be assessed using the Medical Research Council (MRC) sum score. The MRC sum score scale grades voluntary muscle contraction for each muscle group from 0 (no contraction) to 5 (normal strength). Twelve muscle groups will be tested for a total possible best score of 60. A 1-point change in MRC sum score is considered clinically significant.

    Time frame: Day 1 (day of enrollment) and daily in the ICU up to Day 14 or upon ICU discharge whichever comes first.

  2. Change in hand-grip muscle strength measured by handheld dynamometry from ICU admission to hospital discharge.

    Handgrip muscle strength will be assessed using a handheld dynamometer (HHD) as an indicator of global muscle function. Participants will be considered to have ICU-Acquired Weakness (ICUAW) if the average handgrip strength is below the threshold of 11Kg for men or 7 Kg for woman. Higher scores in Kg indicate greater global muscle function.

    Time frame: Day 1 (day of enrollment) and daily in the ICU up to Day 14, and on hospital discharge day.

  3. Change in mobility status assessed by ICU Mobility Scale (IMS) from ICU admission to ICU discharge.

    Functional mobility will be assessed using the ICU Mobility Scale (IMS), which ranges from 0 (lying in bed, no active movement) to 10 (walking independently without a gait aid). Higher scores indicate greater mobility.

    Time frame: Day 1 (day of enrollment) and daily in the ICU up to Day 14 or upon ICU discharge whichever comes first.

  4. Change in functional exercise capacity assessed by Six-Minute Walk Test (6MWT) between ICU discharge to hospital discharge.

    Functional exercise capacity will be assessed using the Six-Minute Walk Test (6MWT) which measures the distance a participant can walk on a flat surface in six minutes. A greater distance walked indicates better functional status.

    Time frame: Measured on the day of ICU discharge, average day 7, and on the day of hospital discharge, average day 14.

  5. Change in functional exercise capacity assessed by 30-Second Sit-to-Stand Test (30 s STS) between ICU discharge to hospital discharge.

    Functional exercise capacity will be assessed using the 30-Second Sit-to-Stand Test (30 s STS) which measures how many times a person can stand up from and sit down (one repetition) in an armless chair in 30 seconds. A higher number of repetitions indicates greater functional capacity.

    Time frame: Measured on the day of ICU discharge, average day 7, and on the day of hospital discharge, average day 14.

  6. Change in Rectus Femoris muscle structure assessed by musculoskeletal ultrasound from ICU admission to hospital discharge.

    The Rectus Femoris muscle structure will be evaluated using musculoskeletal ultrasound. Measurements will include cross-sectional area, muscle circumference, pennation angle, and echo-intensity. Higher cross-sectional area, muscle circumference, and pennation angle indicate better muscle structure, while increased echo-intensity suggests worse muscle structure.

    Time frame: From ICU admission to day 14.

  7. Change in frailty status assessed by Clinical Frailty Scale (CFS) from ICU admission to 3-month post hospital discharge.

    Frailty will be assessed using the Clinical Frailty Scale (CFS), which ranges from 1 (very fit) to 7 (severely frail). Higher scores are worse.

    Time frame: Enrollment to 3-month follow-up.

  8. Change in functional independence assessed by Barthel Index from ICU discharge to hospital discharge.

    Functional independence will be assessed using the Barthel Index, which measures patient's ability in 10 activities of daily living (feeding, bathing, grooming, dressing, bowel control, bladder control, toilet use, chair transfers, mobility on level surfaces, and stairs). A higher score closer to 100 indicate greater functional independence.

    Time frame: Enrollment to 3-month follow-up.

  9. Change in fatigue severity assessed by Visual Analog Scale for Fatigue (VAS-F) from ICU admission to hospital discharge.

    Fatigue will be assessed using the Visual Analog Scale for Fatigue (VAS-F), where participants rate their fatigue on a scale from 0 (no fatigue) to 10 (worst possible fatigue). Higher scores indicate greater fatigue.

    Time frame: From ICU admission up to Day 14 or upon ICU discharge whichever comes first.

  10. Change in health-related quality of life assessed by the RAND 36-Item Health Survey (SF-36) from the time of hospital discharge to 3-month follow-up after hospital discharge.

    Health-related quality of life will be assessed using the RAND 36-Item Health Survey (SF-36), which evaluates eight domains including physical functioning, role limitations, pain, general health, vitality, social functioning, emotional well-being, and mental health. Scores range from 0 to 100, with higher scores indicating better health status.

    Time frame: Hospital discharge to 3-month follow-up after hospital discharge.

  11. Change in employment status and work ability after hospital discharge.

    Employment status will be assessed during follow-up after hospital discharge using a structured questionnaire. Participants will report their current employment status and whether their ICU stay affected their ability to work. Return to work is considered best outcome.

    Time frame: From ICU discharge to 3-month follow up after hospital discharge.

  12. Duration of mechanical ventilation.

    The number of days from the initiation of mechanical ventilation to the discontinuation of mechanical ventilation. A lower number of days is better.

    Time frame: From ICU admission to ICU discharge, an average of 7 days.

  13. Number of ventilator-free days within 28 days after ICU admission.

    Ventilator-free days will be calculated as 28 minus total number of days on invasive mechanical ventilation during which the participant is alive and not receiving invasive mechanical ventilation. Participants who die within 28 days will be assigned zero ventilator-free days.

    Time frame: From extubation to day 28.

  14. Number of days in ICU, hospital ward, and total hospital stay from admission to discharge.

    Length of stay will be recorded in three categories: (1) ICU stay, defined as the total number of consecutive days from ICU admission to ICU discharge; (2) ward stay, defined as the number of days spent in a hospital ward after ICU discharge; and (3) total hospital stay, defined as the number of days from hospital admission to hospital discharge. The shorter the length of stay, the better.

    Time frame: From hospital admission to hospital discharge, an average of 14 days.

  15. Discharge location after hospital stay.

    Discharge location will be recorded at the time of hospital discharge using predefined categories: home, home with home health services, inpatient rehabilitation facility, skilled nursing facility, long-term acute care hospital, hospice, or death. Discharge home is considered the best outcome.

    Time frame: At the last day of hospitalization, average day 14.

  16. Number of participants tolerating electrical muscle stimulation sessions during ICU stay.

    Treatment session tolerance will be assessed using standardized scales. Tolerance is defined as: * CPOT less than 7 * NRS less than 8 at the thigh level * RASS less than +3 Scale ranges: * CPOT (0 = relaxed, 8 = severe pain/agitation) * NRS for pain (0 = no pain, 10 = worst pain), * RASS (-5 = unarousable, +4 = combative)

    Time frame: From day 1 in the ICU up to 7 days or ICU discharge whichever comes first.

  17. Number of participants with electrical interference on ECG monitoring during the stimulation sessions in the ICU.

    Electrical interference with cardiac monitoring will be assessed during each electrical muscle stimulation (EMS) session using ECG tracings from standard ICU cardiac monitoring devices. Interference is defined as continuous 60-cycle (60 Hz) artifact for more than 60 seconds that impairs accurate interpretation of cardiac rhythm. ECG data will be captured only during EMS intervention sessions. Success is defined as 20% or less of ECG samples showing electrical interference as defined above.

    Time frame: From day 1 in the ICU up to 7 days or ICU discharge whichever comes first.

  18. Number of participants achieving significant muscle contraction during electrical muscle stimulation sessions as assessed by Muscle Contraction Scale during the ICU stay.

    "Muscle contraction during electrical muscle stimulation (EMS) sessions will be assessed using the Muscle Contraction Scale, which classifies contraction from Type 1 (no palpable or visible contraction) to Type 5 (palpable and visible contraction with full muscle bulk). Participants achieved a response if they scored muscle contraction grade 3 or higher.

    Time frame: From day 1 in the ICU up to 7 days or ICU discharge whichever comes first.

Other outcomes

  1. Change in Impedance (Z), Reactance (X), and Phase Angle (PA) of the quadriceps muscle during the hospital stay.

    Quadriceps muscle electrical properties will be measured using Electrical Impedance Myography (EIM). Measurements will include Impedance (Z in ohms), Reactance (X in ohms), and Phase Angle (PA in degrees), which reflect muscle composition. Lower Phase Angle and Reactance values indicate reduced muscle composition. Higher Impedance values generally indicate reduced muscle health.

    Time frame: From day 1 up to hospital discharge or day 14 whichever comes first.

  2. Change in C-Terminal Agrin Fragment (CAF) level in blood and urine from enrollment to day 14.

    C-Terminal Agrin Fragment (CAF) levels will be measured in blood and urine samples collected from enrollment through Day 14. Higher CAF levels may indicate increased neuromuscular junction degradation, while lower levels suggest better preservation of muscle function.

    Time frame: From enrollment to day 14.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.

Of 326 interventional studies with no phase under Sepsis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 23, 2026
StartActual
May 5, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07362862
Lead sponsor
Health Discovery Labs
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
May 5, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jul 10, 2026

Study contacts

Oussama Hassan, M.D.
Contact
O.Hassan@healthdiscoverylabs.com
512-203-9474
Grace RH McDonough, MD Candidate, Class of 2030
Contact
G.McDonough@healthdiscoverylabs.com
Oussama Hassan, M.D.
principal investigator · Health Discovery Labs

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion